Nurix Therapeutics Inc [NRIX] stock prices are down -0.09% to $10.63 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The NRIX shares have gain 6.41% over the last week, with a monthly amount drifted -7.81%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nurix Therapeutics Inc [NASDAQ: NRIX] stock has seen the most recent analyst activity on March 17, 2025, when Leerink Partners initiated its Market Perform rating and assigned the stock a price target of $16. Previously, BTIG Research started tracking the stock with Buy rating on December 10, 2024, and set its price target to $35. On December 06, 2024, BMO Capital Markets initiated with a Outperform rating and assigned a price target of $35 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $35 on October 24, 2024. Jefferies initiated its recommendation with a Buy and recommended $41 as its price target on October 11, 2024. In a note dated July 31, 2024, Truist initiated an Buy rating and provided a target price of $36 on this stock.
The stock price of Nurix Therapeutics Inc [NRIX] has been fluctuating between $8.18 and $29.56 over the past year. Currently, Wall Street analysts expect the stock to reach $22.67 within the next 12 months. Nurix Therapeutics Inc [NASDAQ: NRIX] shares were valued at $10.63 at the most recent close of the market. An investor can expect a potential return of 113.26% based on the average NRIX price forecast.
Analyzing the NRIX fundamentals
The Nurix Therapeutics Inc [NASDAQ:NRIX] reported sales of 56.42M for trailing twelve months, representing a surge of 11.26%. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at -4.09%, Pretax Profit Margin comes in at -3.69%, and Net Profit Margin reading is -3.69%. To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -0.47 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.31 points at the first support level, and at 9.99 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.84, and for the 2nd resistance point, it is at 11.05.
Ratios To Look Out For
It’s worth pointing out that Nurix Therapeutics Inc [NASDAQ:NRIX]’s Current Ratio is 6.26. Further, the Quick Ratio stands at 6.26, while the Cash Ratio is 0.84. Considering the valuation of this stock, the price to sales ratio is 14.36, the price to book ratio is 1.69.
Transactions by insiders
Recent insider trading involved van Houte Hans, Chief Financial Officer, that happened on May 02 ’25 when 6198.0 shares were sold. Officer, JOHANNES VAN HOUTE completed a deal on May 02 ’25 to buy 6198.0 shares. Meanwhile, Chief Scientific Officer Hansen Gwenn sold 3377.0 shares on Apr 30 ’25.
